Brief: Ipsen Says 45.7% Spasticity Rate In Stroke Survivors In EPITOME Trial

Ipsen SA

14/01/2026 06:10

Jan 14 (Reuters) - Ipsen SA IPN.PA:

NEW DATA REINFORCES IPSEN’S COMMITMENT TO BRINGING SOLUTIONS AND ADDRESSING CARE GAPS IN NEUROLOGICAL DISEASES AT TOXINS

INTERIM DATA FROM THE ONGOING EPITOME TRIAL SHOWED THAT 45.7% OF STROKE SURVIVORS DEVELOP SPASTICITY WITHIN 1 YEAR

Source text: ID: nGNX4Shcf3

Further company coverage: IPN.PA

(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00; ))